Bioventus Inc. (NYSE:BVS) Stake Raised by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Bioventus Inc. (NYSE:BVS) by 35.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,181 shares of the company’s stock after acquiring an additional 4,513 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Bioventus were worth $157,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BVS. Tower Research Capital LLC TRC raised its position in Bioventus by 106.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after acquiring an additional 1,786 shares in the last quarter. GAMMA Investing LLC raised its position in Bioventus by 3,228.7% in the first quarter. GAMMA Investing LLC now owns 5,792 shares of the company’s stock worth $53,000 after acquiring an additional 5,618 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new stake in Bioventus in the fourth quarter worth about $111,000. ProShare Advisors LLC bought a new stake in Bioventus in the fourth quarter worth about $113,000. Finally, Balyasny Asset Management L.P. bought a new stake in Bioventus in the fourth quarter worth about $133,000. 62.94% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on BVS shares. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the stock a “buy” rating in a research report on Wednesday, May 7th. Cantor Fitzgerald began coverage on Bioventus in a report on Monday, July 7th. They set an “overweight” rating and a $12.00 price objective on the stock.

Bioventus Price Performance

NYSE BVS opened at $6.92 on Monday. The stock’s 50-day moving average price is $6.67 and its two-hundred day moving average price is $7.99. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The company has a market cap of $568.44 million, a PE ratio of -11.34 and a beta of 0.83. Bioventus Inc. has a 1 year low of $5.81 and a 1 year high of $14.38.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.